HOME >> BIOLOGY >> NEWS
UCSF studies illuminate possible new landscape for targeting cancer

Dual UCSF findings dramatize what scientists have just begun to recognize: While so-called oncogenic cells drive the development of cancerous tumors, other, seemingly innocent cells -- inflammatory cells - within emerging tumors can influence the fate of tumors, their aggression and their response to therapy.

The findings, both reported in recent publications, suggest that blocking the action of these 'innocent' cells - or the factors they release - may interrupt the progression of cancerous tumors at early stages of development, the researchers say.

"Tumor biology has historically focused on the cells that contain oncogenic or tumor-suppressor gene mutations. But the combined implication of our two studies suggests that we need to look beyond the mutated tumor cells and into their micro-environment, to take into account the regulation of inflammatory cells," says the lead author of one study, published in Cell, Lisa Coussens, PhD, assistant professor of pathology and a member of the UCSF Comprehensive Cancer Center.

In the Cell study, the researchers report that an enzyme known as matrix metalloproteinase-9 (MMP-9) significantly influences the progression of cancer development in mice engineered to express oncogenes, or tumor-causing genes, that predispose animals to develop squamous cell carcinomas, a common skin cancer in humans. Moreover, the researchers demonstrate that the primary source of the enzyme is not the oncogenic epithelial cells that drive the cancer, but immune inflammatory cells within the tumor's developing mass.

In the other study, published in Nature Cell Biology, the researchers demonstrate that the same enzyme is a key component of the "switch" that initiates angiogenesis, the growth of blood vessels, in mice genetically engineered to develop carcinomas of the pancreatic islets. Angiogenesis supplies emerging tumors with the nutrients and oxygen that are essential for fueling their progressi
'"/>

Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
14-Mar-2001


Page: 1 2 3 4 5

Related biology news :

1. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
2. UCSD undergraduates participate in collaborative studies abroad on cyberinfrastructure
3. Scientist honored for studies of genetic influence on chemotherapy, tumor development
4. $5 million grant funds partnership, studies of minority-based issues in reproductive health
5. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
6. $5.5 million awarded to tree-ring research and climate studies
7. Pancreatic cancer blood test & gene studies show promise
8. Two studies weigh in on low-carb diets
9. Animal studies show promise treating severe chronic pain
10. New studies show Curves Program raises metabolic rate in overweight and sedentary women
11. Florida Tech researchers win $912,700 grant for cell studies

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... 2017  VMS BioMarketing, a leading provider of patient support ... Nurse Educator (CNE) network, which will launch this week. The ... health care professionals to enhance the patient care experience by ... other health care professionals to help women who have been ... ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
(Date:10/10/2017)... ... ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, Inc. spent ... entitled “Stem Cells and Their Regenerative Powers,” was held on August 31st, 2017 ... joined by two human doctors: Peter B. Hanson, M.D., Chief of Orthopedic Surgery, Grossmont ...
Breaking Biology Technology:
Cached News: